Bristol ends Corgentech collaboration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb is terminating a development agreement with Corgentech for the coronary artery bypass graft agent edifoligide (E2F decoy). The agent failed to meet primary or secondary endpoints in a Phase III vein graft failure study, the firms say March 30. Corgentech has no further development plans for edifoligide beyond completing an ongoing Phase I trial. The company will instead focus on a NF-kappaB decoy for eczema...